 | • レポートコード：MRC2305A032 • 出版社/出版日：Transparency Market Research / 2023年3月29日 • レポート形態：英文、PDF、162ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥811,300 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,231,300 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,651,300 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界のうっ血性心不全治療薬市場規模が、2023年の67億ドルから2031年に135億ドルとなり、予測期間中に年平均7.6%で成長すると推測されています。本レポートは、うっ血性心不全治療薬の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、うっ血性心不全種類別（左心不全、右心不全、高拍出性心不全）分析、治療薬クラス別（ACE阻害剤、アンジオテンシンⅡ受容体拮抗薬、β遮断薬、ミネラロコルチコイド受容体拮抗薬、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の項目を整理しています。また、Bayer AG、Novartis AG、Merck & Co., Inc.、AstraZeneca、Bristol-Myers Squibb Company、Amgen, Inc.、Boehringer Ingelheim International GmbH、Pfizer, Inc.、Johnson & Johnson Services, Inc.、Eli Lilly and Companyなど、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界のうっ血性心不全治療薬市場規模：うっ血性心不全種類別 - 左心不全の市場規模 - 右心不全の市場規模 - 高拍出性心不全の市場規模 ・世界のうっ血性心不全治療薬市場規模：治療薬クラス別 - ACE阻害剤の市場規模 - アンジオテンシンⅡ受容体拮抗薬の市場規模 - β遮断薬の市場規模 - ミネラロコルチコイド受容体拮抗薬の市場規模 - その他治療薬クラスの市場規模 ・世界のうっ血性心不全治療薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のうっ血性心不全治療薬市場規模：地域別 - 北米のうっ血性心不全治療薬市場規模 - ヨーロッパのうっ血性心不全治療薬市場規模 - アジア太平洋のうっ血性心不全治療薬市場規模 - 中南米のうっ血性心不全治療薬市場規模 - 中東・アフリカのうっ血性心不全治療薬市場規模 ・競争状況 |
Congestive Heart Failure Drugs Market – Scope of Report
TMR’s report on the global congestive heart failure drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global congestive heart failure drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global congestive heart failure drugs market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the congestive heart failure drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global congestive heart failure drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global congestive heart failure drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global congestive heart failure drugs market.
The report delves into the competitive landscape of the global congestive heart failure drugs market. Key players operating in the global congestive heart failure drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global congestive heart failure drugs market profiled in this report.
Key Questions Answered in Global Congestive Heart Failure Drugs Market Report
• What is the sales/revenue generated by congestive heart failure drugs across all regions during the forecast period?
• What are the opportunities in the global congestive heart failure drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Congestive Heart Failure Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global congestive heart failure drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global congestive heart failure drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global congestive heart failure drugs market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Congestive Heart Failure Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Congestive Heart Failure Drugs Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. Pipeline Analysis
5.3. Heart Failure Diseases Prevalence: Overview
6. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Type of Digestive Heart Failure
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
6.3.1. Left-sided Heart Failure
6.3.2. Right-sided Heart Failure
6.3.3. High-output Heart Failure
6.4. Market Attractiveness Analysis, by Type of Digestive Heart Failure
7. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. ACE Inhibitors
7.3.2. Angiotensin-2 Receptor Blockers
7.3.3. Beta Blockers
7.3.4. Mineralocorticoid Receptor Antagonists
7.3.5. Diuretics
7.3.6. Ivabradine
7.3.7. Sacubitril Valsartan
7.3.8. Others (digoxin etc.)
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospitals Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Congestive Heart Failure Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Congestive Heart Failure Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
10.2.1. Left-sided Heart Failure
10.2.2. Right-sided Heart Failure
10.2.3. High-output Heart Failure
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. ACE Inhibitors
10.3.2. Angiotensin-2 Receptor Blockers
10.3.3. Beta Blockers
10.3.4. Mineralocorticoid Receptor Antagonists
10.3.5. Diuretics
10.3.6. Ivabradine
10.3.7. Sacubitril Valsartan
10.3.8. Others (digoxin etc.)
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospitals Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Digestive Heart Failure
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Congestive Heart Failure Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
11.2.1. Left-sided Heart Failure
11.2.2. Right-sided Heart Failure
11.2.3. High-output Heart Failure
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. ACE Inhibitors
11.3.2. Angiotensin-2 Receptor Blockers
11.3.3. Beta Blockers
11.3.4. Mineralocorticoid Receptor Antagonists
11.3.5. Diuretics
11.3.6. Ivabradine
11.3.7. Sacubitril Valsartan
11.3.8. Others (digoxin etc.)
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospitals Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Digestive Heart Failure
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Congestive Heart Failure Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
12.2.1. Left-sided Heart Failure
12.2.2. Right-sided Heart Failure
12.2.3. High-output Heart Failure
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. ACE Inhibitors
12.3.2. Angiotensin-2 Receptor Blockers
12.3.3. Beta Blockers
12.3.4. Mineralocorticoid Receptor Antagonists
12.3.5. Diuretics
12.3.6. Ivabradine
12.3.7. Sacubitril Valsartan
12.3.8. Others (digoxin etc.)
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospitals Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Digestive Heart Failure
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Congestive Heart Failure Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
13.2.1. Left-sided Heart Failure
13.2.2. Right-sided Heart Failure
13.2.3. High-output Heart Failure
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. ACE Inhibitors
13.3.2. Angiotensin-2 Receptor Blockers
13.3.3. Beta Blockers
13.3.4. Mineralocorticoid Receptor Antagonists
13.3.5. Diuretics
13.3.6. Ivabradine
13.3.7. Sacubitril Valsartan
13.3.8. Others (digoxin etc.)
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospitals Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type of Digestive Heart Failure
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Congestive Heart Failure Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Digestive Heart Failure, 2017–2031
14.2.1. Left-sided Heart Failure
14.2.2. Right-sided Heart Failure
14.2.3. High-output Heart Failure
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. ACE Inhibitors
14.3.2. Angiotensin-2 Receptor Blockers
14.3.3. Beta Blockers
14.3.4. Mineralocorticoid Receptor Antagonists
14.3.5. Diuretics
14.3.6. Ivabradine
14.3.7. Sacubitril Valsartan
14.3.8. Others (digoxin etc.)
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospitals Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type of Digestive Heart Failure
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Bayer AG
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. AstraZeneca
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Amgen, Inc.
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. Boehringer Ingelheim International GmbH
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. Pfizer, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Johnson & Johnson Services, Inc.
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. Eli Lilly and Company
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Business Strategies
15.3.10.5. Recent Developments